Pyruvate Kinase R Activators for Hemolytic Anemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for pyruvate kinase deficiency (PKD) lack definitive solutions, with existing therapies like splenectomy and hematopoietic stem cell gene therapy associated with adverse effects, and there is a need for effective PKR activating compounds to modulate pyruvate kinase activity.
Innovation Solution
Development of novel chemical compounds, such as those represented by Formulas I, II, III, and IV, which activate wild-type and mutant forms of pyruvate kinase (PKR) by shifting the enzyme equilibrium to its most active tetrameric form, thereby treating PKD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If splenectomy or hematopoietic stem cell gene therapy is performed, then definitive treatment of PKD is achieved, but adverse effects and surgical complexity increase
Solution Approach 1:
The patent changes the molecular parameters of PKR by introducing small molecule compounds that bind to the enzyme and induce conformational changes, shifting the equilibrium from dimeric to tetrameric form. This parameter change activates PKR without requiring complex surgical interventions or gene therapy procedures.
Solution Approach 2:
The patent uses small molecule compounds as intermediaries to activate PKR. These compounds serve as mediators between the administered drug and the target enzyme, binding to PKR and inducing tetramer formation without requiring direct genetic modification or surgical removal of organs.
2Adaptability or versatility
If PKR activating compounds are developed, then treatment targeting specificity is improved, but compound structure complexity increases
Solution Approach 1:
The patent achieves local quality by designing compounds with specific molecular features that target particular regions or conformational states of PKR. The compounds are structured to bind specifically to the enzyme and induce tetramer formation, providing targeted activation without requiring overly complex structures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively activate PKR, potentially offering a more targeted and less invasive treatment for PKD by enhancing pyruvate kinase activity, thereby alleviating hemolytic anemia associated with the deficiency.
Implementation Method 1
Small molecules have been shown to be capable of shifting the equilibrium of PKR to the tetrameric (most active) form
Data Source
AI summary
The disclosure provides novel chemical compounds useful as activators of PKR. PKR activating compounds are useful in the treatment of disease and disorders associated with modulation of PKR and/or PKM2, such as pyruvate kinase deficiency (PKD).